The TONIC trial: A step forward in treating pediatric nonalcoholic fatty liver disease
Naim Alkhouri, Ariel E. Feldstein – 27 March 2012
Increasing the recipient benefit/donor risk ratio by lowering the graft size requirement for living donor liver transplantation
See Ching Chan, Sheung Tat Fan, Kenneth S. H. Chok, William W. Sharr, Wing Chiu Dai, James Y. Y. Fung, Kwok Yin Chan, Dharmesh J. Balsarkar, Chung Mau Lo – 27 March 2012 – In living donor liver transplantation (LDLT), a right liver graft is larger than a left liver graft and hence leads to better recipient survival. However, in comparison with donor left hepatectomy, donor right hepatectomy carries a higher donor risk.
Association of AKI With mortality and complications in hospitalized patients with cirrhosis
Justin M. Belcher, Guadalupe Garcia‐Tsao, Arun J. Sanyal, Harjit Bhogal, Joseph K. Lim, Naheed Ansari, Steven G. Coca, Chirag R. Parikh, for the TRIBE‐AKI Consortium – 27 March 2012 – Acute kidney injury (AKI) is a common and devastating complication in patients with cirrhosis. However, the definitions of AKI employed in studies involving patients with cirrhosis have not been standardized, lack sensitivity, and are often limited to narrow clinical settings.
Efficient replication of primary or culture hepatitis C virus isolates in human liver slices: A relevant ex vivo model of liver infection
Sylvie Lagaye, Hong Shen, Bertrand Saunier, Michelina Nascimbeni, Jesintha Gaston, Pierre Bourdoncle, Laurent Hannoun, Pierre‐Philippe Massault, Anaïs Vallet‐Pichard, Vincent Mallet, Stanislas Pol – 27 March 2012 – The development of human cultured hepatitis C virus (HCV) replication‐permissive hepatocarcinoma cell lines has provided important new virological tools to study the mechanisms of HCV infection; however, this experimental model remains distantly related to physiological and pathological conditions.
Diabetes and hepatocellular cancer risk: Not only a matter of hyperglycemia
Giulio Marchesini, Gabriele Forlani – 27 March 2012
Correction
20 March 2012
Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial
Thuy‐Anh Le, Joshua Chen, Christopher Changchien, Michael R. Peterson, Yuko Kono, Heather Patton, Benjamin L. Cohen, David Brenner, Claude Sirlin, Rohit Loomba, for the San Diego Integrated NAFLD Research Consortium (SINC) – 20 March 2012 – Bile acid sequestrants (BAS) lower plasma low density lipoprotein levels and improve glycemic control. Colestimide, a BAS, has been claimed by computed tomography to reduce liver fat. Therefore, we examined the efficacy of colesevelam, a potent BAS, to decrease liver fat in patients with biopsy‐proven nonalcoholic steatohepatitis (NASH).
Hepatitis C virus infection enhances TNFα‐induced cell death via suppression of NF‐κB
Junseong Park, Wonseok Kang, Seung‐Wook Ryu, Woo‐Il Kim, Dong‐Yeop Chang, Dong Ho Lee, Do Youn Park, Youn‐Hee Choi, Kyungsun Choi, Eui‐Cheol Shin, Chulhee Choi – 20 March 2012 – Hepatitis C virus (HCV) infection results in liver injury and long‐term complications, such as liver cirrhosis and hepatocellular carcinoma. Liver injury in HCV infection is believed to be caused by host immune responses, not by viral cytopathic effects. Tumor necrosis factor‐alpha (TNF‐α) plays a pivotal role in the inflammatory processes of hepatitis C.